RFP
ALNY icon

Root Financial Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Root Financial Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-79
Closed -$26.1K – 515
2026
Q1 		$26.1K Buy
79
+17
+27% +$5.79K ﹤0.01% 1176
2025
Q4 		$24.7K Buy
62
+8
+15% +$3.54K ﹤0.01% 1071
2025
Q3 		$24.6K Buy
+54
New +$22K ﹤0.01% 1007

Other funds holding ALNY

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
FAF
Fjarde Ap-fonden Stockholm, Sweden $20.9B AUM 36.93% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Asset Management One
Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return

Root Financial Partners's ALNY Position: Q2 2026 in Review

Root Financial Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 79 shares — an estimated $26.1K sold.

Root Financial Partners first reported a position in ALNY in Q3 2025 and held it in 3 quarters. The position peaked at $26.1K in Q1 2026. 211 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Root Financial Partners reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Root Financial Partners sold 79 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $26.1K.
  • Root Financial Partners first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Root Financial Partners's Alnylam Pharmaceuticals position peaked at $26.1K in Q1 2026.
  • 211 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.